<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02703740</url>
  </required_header>
  <id_info>
    <org_study_id>15F/IALE01</org_study_id>
    <nct_id>NCT02703740</nct_id>
  </id_info>
  <brief_title>Long Term Safety and Efficacy Assessment of Hyaluronic Acid Dermal Filler With for the Treatment of Nasolabial Folds</brief_title>
  <acronym>ECLAH</acronym>
  <official_title>Long Term Safety and Efficacy Assessment of Hyaluronic Acid Dermal Filler With for the Treatment of Nasolabial Folds</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratoires Genévrier</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratoires Genévrier</source>
  <brief_summary>
    <textblock>
      This study evaluates the injection of a hyaluronic acid dermal filler with lidocaine 0.3% in
      the treatment of nasolabial folds (NLF). Each patient will receive 1 concentration in a NLF
      (20 mg/mL) and an other concentration in the other NLF (24 mg/mL).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Interventional, monocentric, double blind, randomised study Evaluation of safety the 1st
      month (primary criteria) and until 12 month Evaluation of performance at baseline, month 3,
      month 6, month 9 and month 12 : WSRS (wrinkle scale), profilometry (image measuring wrinkle
      depth and area), GAIS : satisfaction scale
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 11, 2016</start_date>
  <completion_date type="Actual">February 3, 2017</completion_date>
  <primary_completion_date type="Actual">February 3, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and description of adverse events that are related to treatment</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and description of adverse events that are related to treatment</measure>
    <time_frame>72h/3 months/6 Months/9 months/12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment efficacy assessed by WSRS</measure>
    <time_frame>1/3/6/9/12 months</time_frame>
    <description>WSRS (wrinkle severity rating scale) : a 5-point validated scale ranging from 1 (absent) to 5 (extreme).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Aesthetics</condition>
  <arm_group>
    <arm_group_label>HA 20 mg/mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>HA 24 mg/mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hyaluronic acid dermal filler with lidocaine 0.3%</intervention_name>
    <description>injection in labial fold of a dermal filler</description>
    <arm_group_label>HA 20 mg/mL</arm_group_label>
    <arm_group_label>HA 24 mg/mL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Is at least 19 years of age.

          -  Has Fitzpatrick Skin Type IV, V, or VI.

          -  Has a WSRS score &gt; or = to 3 for both NLF

          -  Understands and accepts the obligation not to receive any other procedures or
             treatments in the nasolabial fold for 6 months

        Exclusion Criteria:

        Has keloid formation, or hypertrophic scarring or dyschromic scaring. Has hypersensitivity
        to hyaluronic acid, Chlorhexidine lidocaine or local anaesthetic drugs

          -  Has a known bleeding disorder or is receiving drug therapy that could increase the
             risk of bleeding.

          -  Has nasolabial folds that are too severe to be corrected in one treatment session.

          -  Has received any dermal filler or other injections, grafting or surgery in either
             nasolabial fold during the last year.

          -  Is pregnant, lactating, or not using acceptable contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CREABIO</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>January 18, 2016</study_first_submitted>
  <study_first_submitted_qc>March 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2016</study_first_posted>
  <last_update_submitted>October 10, 2019</last_update_submitted>
  <last_update_submitted_qc>October 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

